

# Human Recombinant ADRA1B Adrenoceptors Stable Cell Line

Technical Manual No. TM0416

Version 10132010

I	Introduction .....	1
II	Background.....	1
III	Representative Data.....	2
IV	Thawing and Subculturing.....	3
V	References .....	3
	Limited Use License Agreement.....	4

## I. Introduction

Catalog Number: M00260

Cell Line Name: CHO-K1/ADRA1B

Expressed Gene: GenBank Accession Number NM 000679; no expressed tags

Host Cell: CHO-K1

Quantity: Two vials of frozen cells ( $3 \times 10^6$  per vial)

Stability: 16 passages

Applications: Functional assays for ADRA1B receptors

Freeze Medium: 45% culture medium, 45%FBS, and 10%DMSO

Complete Growth Medium: Ham's F12, 10% FBS

Culture Medium: Ham's F12, 10% FBS, 400  $\mu\text{g/ml}$  G418

Mycoplasma Status: Negative


Storage: Liquid nitrogen immediately upon delivery

## II. Background

The  $\alpha_1$ -adrenergic receptor (AR) family consists of three closely related gene products ( $\alpha_{1A}$ ,  $\alpha_{1B}$ , and  $\alpha_{1D}$ ). They mediate the actions of norepinephrine (NE) and epinephrine in sympathetically innervated tissues and brain.  $\alpha_1$ -ARs belong to the G protein-coupled receptor family and consist of single polypeptide chains that are predicted to form seven transmembrane spanning domains. With similar pharmacological and signaling properties,  $\alpha_1$ -AR subtypes act through  $G_{q/11}$  proteins to activate phospholipase C, increase inositol 1,4,5-trisphosphate production, and increase intracellular  $\text{Ca}^{2+}$ . ADRA1B functions in diverse settings include vasoconstriction and myocardial contractility, neuronal dopaminergic responses, dendritic cell migration and inflammatory responses, as well as neuroendocrine regulation of fertility.

### III. Representative Data

Concentration-dependent stimulation of intracellular calcium mobilization by Epinephrine in CHO-K1/ADRA1B and CHO-K1 cells



**Figure 1.** Epinephrine-induced concentration-dependent stimulation of intracellular calcium mobilization in CHO-K1/ADRA1B and CHO-K1 cells. The cells were loaded with Calcium-4 prior to stimulation with a ADRA1B receptor agonist, Epinephrine. The intracellular calcium change was measured by FlexStation. The relative fluorescent units (RFU) were plotted against the log of the cumulative doses (10-fold dilution) of Epinephrine (Mean  $\pm$  SD, n = 2). The EC<sub>50</sub> of Epinephrine on ADRA1B in CHO-K1 cells was 44 nM. The S/B of Epinephrine on ADRA1B in CHO-K1 cells was 19.

Notes:

- EC<sub>50</sub> value is calculated with four parameter logistic equation:  

$$Y = \text{Bottom} + (\text{Top} - \text{Bottom}) / (1 + 10^{-(\text{LogEC}_{50} - X) \cdot \text{HillSlope}})$$

X is the logarithm of concentration. Y is the response  
 Y is RFU and starts at Bottom and goes to Top with a sigmoid shape.
- Signal to background Ratio (S/B) = Top/Bottom

### IV. Thawing and Subculturing

Thawing: Protocol

- Remove the vial from liquid nitrogen tank and thaw cells quickly in a 37°C water-bath.
- Just before the cells are completely thawed, decontaminate the outside of the vial with 70% ethanol and transfer the cells to a 15 ml centrifuge tube containing 9 ml of complete growth medium.
- Pellet cells by centrifugation at 200 x g force for 5 min, and discard the medium.
- Resuspend the cells in complete growth medium.
- Add 10 ml of the cell suspension in a 10 cm dish.
- Add G418 to a concentration of 400 µg/ml the following day.

Subculturing: Protocol

1. Remove and discard culture medium.
2. Wash cells with PBS (pH=7.4) to remove all traces of serum that contains trypsin inhibitor.
3. Add 2.0 ml of 0.05% (w/v) Trypsin- EDTA (GIBCO, Cat No. 25300) solution to 10 cm dish and observe the cells under an inverted microscope until cell layer is dispersed (usually within 3 to 5 minutes).  
Note: To avoid clumping, do not agitate the cells by hitting or shaking the dish while waiting for the cells to detach. Cells that are difficult to detach may be placed at 37°C to facilitate dispersal.
4. Add 6.0 to 8.0 ml of complete growth medium and aspirate cells by gently pipetting, centrifuge the cells 200 x g force for 5min, and discard the medium.
5. Resuspend the cells in culture medium and add appropriate aliquots of the cell suspension to new culture vessels.
6. Incubate cultures at 37°C.

Subcultivation Ratio: 1:3 to 1:8 weekly.

Medium Renewal: Every 2 to 3 days

## V. References

1. Vicentic, A., Robeva, A., Rogge, G., Uberti, M. and Minneman, K.P.(2002) Biochemistry and Pharmacology of Epitope-Tagged  $\alpha_1$ --Adrenergic Receptor Subtypes *J. Pharmacol. Exp. Ther.*, 302: 58-65
2. Zhong H and Minneman KP (1999a)  $\alpha_1$ -Adrenoceptor subtypes. *Eur J Pharmacol* 375:261–276.
3. Ruffolo RR Jr, Stadel JM, and Hieble JP (1994)  $\alpha_1$ -Adrenoceptors: recent developments. *Med Res Rev* 14:229–270.

GenScript USA Inc.  
860 Centennial Ave., Piscataway, NJ 08854  
Tel: 732-885-9188, 732-885-9688  
Fax: 732-210-0262, 732-885-5878  
Email: [info@genscript.com](mailto:info@genscript.com)  
Web: <http://www.genscript.com>

**For Research Use Only.**

---

## Limited Use License Agreement

This is a legal agreement between you (Licensee) and GenScript USA Inc. governing use of GenScript's stable cell line products and protocols provided to licensee. By purchasing and using the stable cell line, the buyer agrees to comply with the following terms and conditions of this label license and recognizes and agrees to such restrictions:

- 1) The products are not transferable and will be used at the site where they were purchased. Transfer to another site owned by buyer will be permitted only upon written request by buyer followed by subsequent written approval by GenScript.
- 2) The purchaser cannot sell or otherwise transfer (a) this product (b) its components or (c) materials made using this product or its components to a third party.
- 3) The products sold by GenScript are for laboratory and animal research purposes only. The products are not to be used on humans, for consumption, or for any unlawful uses.

GenScript USA Inc. will not assert against the buyer a claim of infringement of patents owned or controlled by GenScript USA Inc. and claiming this product based upon the manufacture, use or sale of a clinical diagnostic, therapeutic and vaccine, or prophylactic product developed in research by the buyer in which this product or its components has been employed, provided that neither this product nor any of its components was used in the manufacture of such product. For information on the use of this product for other purposes, contact Marketing Department, GenScript USA Inc., 860 Centennial Avenue, Piscataway, New Jersey 08840, U.S.A. Phone: 1-732-885-9188. Fax: 1-732-210-0262. Email: [marketing@genscript.com](mailto:marketing@genscript.com).